MARKET

PRME

PRME

Prime Medicine
NASDAQ
4.010
+0.080
+2.04%
After Hours: 4.040 +0.03 +0.75% 19:59 03/06 EST
OPEN
3.800
PREV CLOSE
3.930
HIGH
4.090
LOW
3.725
VOLUME
2.57M
TURNOVER
--
52 WEEK HIGH
6.94
52 WEEK LOW
1.110
MARKET CAP
723.85M
P/E (TTM)
-2.9658
1D
5D
1M
3M
1Y
5Y
1D
Largest borrow rate increases among liquid names
TipRanks · 3d ago
Wall Street Analysts Are Neutral on Top Healthcare Picks
TipRanks · 3d ago
Prime Medicine GAAP EPS of -$1.35, revenue of $4.63M
Seeking Alpha · 4d ago
Prime Medicine slips after Q4 updates
Seeking Alpha · 4d ago
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME) and Xeris Pharmaceuticals (XERS)
TipRanks · 4d ago
Prime Medicine Reports 2025 Results, Advances Gene Editing Pipeline
TipRanks · 4d ago
Prime Medicine 2025 net loss widens, hurt by higher R&D expenses  
Reuters · 4d ago
Prime Medicine Publishes Corporate Presentation on Prime Editing Platform and Gene-Editing Pipeline
Reuters · 4d ago
More
About PRME
Prime Medicine, Inc. is a biotechnology company engaged in creating and delivering gene editing therapies to patients. It deploys its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. It is advancing a set of high-value programs across its core areas of focus (hematology, immunology and oncology, liver, and lung). These include ex vivo hematopoietic stem cell (HSC) programs for the treatment of p47phox chronic granulomatous disease CGD and X-linked CGD; a lipid nanoparticle (LNP) Prime Editor for the treatment of Wilson’s Disease; a LNP or adeno-associated virus Prime Editors for the treatment of cystic fibrosis; and ex vivo T-cell therapies. PM359, its product candidate within its hematology, immunology and oncology area of focus, targets the p47phox variant of CGD. Its PM577 comprises a Prime Editor encapsulated as RNA cargo in a liver-targeted LNP.

Webull offers Prime Medicine Inc stock information, including NASDAQ: PRME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRME stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRME stock methods without spending real money on the virtual paper trading platform.